BPTH vs. GLMD, PRFX, LSDI, QLGN, INM, CMND, ATNF, NBSE, HSTO, and SLRX
Should you be buying Bio-Path stock or one of its competitors? The main competitors of Bio-Path include Galmed Pharmaceuticals (GLMD), PainReform (PRFX), Lucy Scientific Discovery (LSDI), Qualigen Therapeutics (QLGN), InMed Pharmaceuticals (INM), Clearmind Medicine (CMND), 180 Life Sciences (ATNF), NeuBase Therapeutics (NBSE), Histogen (HSTO), and Salarius Pharmaceuticals (SLRX). These companies are all part of the "pharmaceutical preparations" industry.
Bio-Path (NASDAQ:BPTH) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability.
Galmed Pharmaceuticals' return on equity of -53.29% beat Bio-Path's return on equity.
Bio-Path currently has a consensus price target of $40.00, suggesting a potential upside of 1,398.13%. Given Bio-Path's higher possible upside, equities research analysts plainly believe Bio-Path is more favorable than Galmed Pharmaceuticals.
Bio-Path has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.
In the previous week, Bio-Path and Bio-Path both had 1 articles in the media. Bio-Path's average media sentiment score of 0.50 beat Galmed Pharmaceuticals' score of -0.50 indicating that Bio-Path is being referred to more favorably in the media.
5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 3.1% of Bio-Path shares are owned by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Galmed Pharmaceuticals received 161 more outperform votes than Bio-Path when rated by MarketBeat users. Likewise, 65.77% of users gave Galmed Pharmaceuticals an outperform vote while only 55.53% of users gave Bio-Path an outperform vote.
Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.
Summary
Galmed Pharmaceuticals beats Bio-Path on 9 of the 12 factors compared between the two stocks.
Get Bio-Path News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bio-Path Competitors List
Related Companies and Tools
